Comparison of CYP51A gene expression of Aspergillus fumigatus isolates against fluconazole and nano-fluconazole

Subject Areas : Journal of Comparative Pathobiology

Sarrafha  Sarrafha, ¹ (Department of Pathobiology, Science and Research Branch, Islamic Azad University, Tehran, Iran)
S.J.  Hashemi Hazaveh ² (Department of Medical Parasitology and Mycology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran)
S.  Rezaei ³ (Department of Medical Parasitology and Mycology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran)
M.  Bayat, ⁴ (Department of Pathobiology, Science and Research Branch, Islamic Azad University, Tehran, Iran)

Received: 2022-05-21 Accepted : 2022-05-21 Published : 2021-11-22

Keywords: Aspergillus fumigatus, fluconazole, CYP51A gene, Nanoparticle, minimum inhibitory concentrati,

Abstract :

Aspergillosis is an opportunistic fungal infection in animals. The disease is mainly respiratory, but other disease manifestations also occur in poultry. Researchers have shown that, one of the reasons for the increase in drug resistance in Aspergillus species is the overexpression of the CYP51A gene. This study compared CYP51A gene expression of Aspergillus fumigatus isolated from poultry against fluconazole and nano-fluconazole. Fluconazole liposomal-nanoparticles were prepared by the thin layer hydration method. We dissolved 5.12 mg of fluconazole powder in 1 ml of sterile distilled water and 6 ml of chloroform-methanol organic solvent. We added 51 mg of lecithin and 5 mg of cholesterol to it. The size of nanoparticles was 88.9±12.1 nm and the surface charge of these nanoparticles was -20.12±1.88 mv. We also used a Scanning-Electron Microscope to study the structure of nanoparticles. Thirty samples of A. fumigatus were collected from poultry lung nodules. Minimum inhibitory concentration (MIC) was performed by standard Broth Microdilution method according to NCCLS-M38A2 to evaluate the MIC of fluconazole and nano-fluconazole against isolates. We selected two high-resistance isolates to fluconazole and used them to determine the CYP51A gene expression level by real-time PCR. The results showed that nano-fluconazole had a lower MIC than fluconazole and in lower concentrations of the drug inhibited the growth of Aspergillus fumigatus isolates. CYP51A gene expression was increased in fluconazole and nano-fluconazole-treated isolates compared to the untreated state. Conversely, a decrease in CYP51A gene expression was observed in the exposure to nano-drug compared with the normal drug.

References:

1. Barnes PD. Marr KA. Aspergillosis: spectrum of disease. diagnosis. and treatment. Infectious disease clinics of North America. 2006;20(3):545-61.


2. Walsh TJ. Anaissie EJ. Denning DW. Herbrecht R. Kontoyiannis DP. Marr KA. et al. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clinical Infectious Diseases. 2008;46(3):327-60.


3. Khosravi A.R. Shokri H. Raeiat Yahya R. Veterinary Mycology. Tehran University; 1384.


4. Shadzi S. Medical Mycology. 2nd ed. Isfahan university; 1388.


5. Stevens DA. Lee JY. Analysis of compassionate use itraconazole therapy for invasive aspergillosis by the NIAID Mycoses Study Group criteria. Archives of internal medicine. 1997;157(16):1857-62.


6. Patton LL. Bonito AJ. Shugars DA. A systematic review of the effectiveness of antifungal drugs for the prevention and treatment of oropharyngeal candidiasis in HIV-positive patients. Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics. 2001;92(2):170-9.


7. Verweij PE. Snelders E. Kema GH. Mellado E. Melchers WJ. Azole resistance in Aspergillus fumigatus: a side-effect of environmental fungicide use? The Lancet Infectious diseases. 2009;9(12):789-95.


8. Martel CM. Parker JE. Warrilow AGS. Rolley NJ. Kelly SL. Kelly DE. Complementation of a Saccharomyces cerevisiae ERG11/CYP51 (Sterol 14α-Demethylase) Doxycycline-Regulated Mutant and Screening of the Azole Sensitivity of Aspergillus fumigatus Isoenzymes CYP51A and CYP51B. Antimicrobial Agents and Chemotherapy. 2010;54(11):4920-3.


9. Mellado E. Garcia-Effron G, Alcázar-Fuoli L. Melchers WJG. Verweij PE. Cuenca-Estrella M. et al. A New Aspergillus fumigatus Resistance Mechanism Conferring In Vitro Cross-Resistance to Azole Antifungals Involves a Combination of cyp51A Alterations. Antimicrobial Agents and Chemotherapy. 2007;51(6):1897-904.

10. Fera MT, La Camera E, De Sarro A. New triazoles and echinocandins: mode of action, in vitro activity and mechanisms of resistance. Expert review of anti-infective therapy. 2009;7(8):981-98.


11. Allaker RP. The use of nanoparticles to control oral biofilm formation. Journal of dental research. 2010;89(11):1175-86.


12. Chwalibog A, Sawosz E, Hotowy A, Szeliga J, Mitura S, Mitura K, et al. Visualization of interaction between inorganic nanoparticles and bacteria or fungi. International journal of nanomedicine. 2010;5(12):1085-94.


13. Dua JS, Rana AC, Bhandari AK. Liposome: methods of preparation and applications. International Journal of Pharmaceutical studies and research. 2012;3(2):14-20.


14. Sarrafha MR, Hashemi SJ, Rezaei S, Bayat M. In vitro Evaluation of the Effects of Fluconazole and Nano-Fluconazole on Aspergillus flavus and A. fumigatus Isolates. Jundishapur Journal of Microbiology. 2018;11(6):e57875.


15. El-Nesr OH, Yahiya SA, El-Gazayerly ON. Effect of formulation design and freeze-drying on properties of fluconazole multilamellar liposomes. Saudi Pharmaceutical Journal. 2010;18(4):217-24.


16. John H. Rex, Barbara D. Alexander, David Andes, Beth Arthington-Skagges, Steven D. Brown, Vishnu Chaturveli, et al. M38A2-Reference Method for Broth Dilution Antifungal Susceptibility Testing of Filamentous Fungi; Approved Standard. Clinical and Laboratory standards institute(CLSI). 2008;28(4):1-13.


17. Azam F, Farideh Z, Parivash K, Seyed Jamal H, Mahmoud M, Mahin S. In Vitro Susceptibility of Aflatoxigenic and Non-aflatoxigenic Aspergillus flavus Strains to Conventional Antifungal Agents. Acta Medica Iranica. 2012;50(12):798-804.


18. Moore CB. Sayers N. Mosquera J. Slaven J. Denning DW. Antifungal drug resistance in Aspergillus. Journal of infection. 2000;41(3):203-20.


19. Sabatelli F, Patel R, Mann PA, Mendrick CA, Norris CC, Hare R, et al. In vitro activities of posaconazole, fluconazole, itraconazole, voriconazole, and amphotericin B against a large collection of clinically important molds and yeasts. Antimicrobial Agents and Chemotherapy. 2006;50(6):2009-15.


20. Haghighi F, Mohammadi SR, Khoobi M, Haririan I. Enhancing antifungal activity of itraconazole by mesoporous silica nanoparticles. Journal of Pure and Applied Microbiology. 2015;9(4):2771-81.


21. Howard SJ. Pasqualotto AC. Denning DW. Azole resistance in allergic bronchopulmonary aspergillosis and Aspergillus bronchitis. Clinical Microbiology and Infection. 2010;16(6):683-8.


22. Swaminathan J. Ehrhardt C. Liposomal delivery of proteins and peptides. Expert opinion on drug delivery. 2012;9(12):1489-503.


23. Vikaas B. Bhardwaj B. Choudhary M. Nanotechnology: Applications in pharmaceutical drug delivery systems. Journal of chemical and pharmaceutical research. 2016;8(8):259-65.


24. Mehnert W, Mäder K. Solid lipid nanoparticles: Production, characterization and applications. Advanced Drug Delivery Reviews. 2001;47(2):165-96.


25. Bose S. Du Y. Takhistov P. Michniak-Kohn B. Formulation optimization and topical delivery of quercetin from solid lipid based nanosystems. International Journal of Pharmaceutics. 2013;441(1):56-66.


26. Gupta T. Patial V. Bali D. Angaria S. Sharma M. Chahota R. A review: Lumpy skin disease and its emergence in India. Veterinary Research Communications. 2020;44(3):111-8.


27. Leonardelli F, Macedo D, Dudiuk C, Cabeza MS, Gamarra S, Garcia-Effron G. Aspergillus fumigatus Intrinsic Fluconazole Resistance Is Due to the Naturally Occurring T301I Substitution in Cyp51Ap. Antimicrobial Agents and Chemotherapy. 2016;60(9):5420-6.